- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CH:ROG
Recent news which mentions CH:ROG
Technical strategist Tom DeMark says a top for Nasdaq and Dow could come as early as this week
December 04, 2023
From MarketWatch
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
December 04, 2023
From MarketWatch
Morgan Stanley’s Wilson: Next rally attempt will fail as investors are punishing earnings reports.
October 23, 2023
From MarketWatch
From MarketWatch
Acadia stock rallies on drug news as Roivant also climbs, while Leslie’s, Theseus shares plunge and more moving stocks
July 14, 2023
From MarketWatch
Tags
CH:ROG
From MarketWatch
Tags
CH:ROG
From MarketWatch
This chart gives one reason European stocks may continue to outperform U.S. equities
February 17, 2023
From MarketWatch
Roche profit misses forecasts, sees COVID-19 related sales decline ahead
February 02, 2023
Tags
CH:ROG
From MarketWatch
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividend
February 01, 2023
Tickers
NVS
From MarketWatch
Inflammation after COVID may cause loss of smell, new study finds
December 22, 2022
Tags
CH:ROG
From MarketWatch
Roche’s phase 3 data show Lymphoma treatment can reduce disease risks
December 12, 2022
Tags
CH:ROG
From MarketWatch
What to know about the Alzheimer’s drug data coming out this week
November 28, 2022
From MarketWatch
Roche gets FDA Emergency Use Authorization for Monkeypox virus test
November 16, 2022
Tags
CH:ROG
From MarketWatch
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
From MarketWatch
Tags
CH:ROG
From MarketWatch
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
September 28, 2022
From MarketWatch
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
September 14, 2022
From MarketWatch
From MarketWatch
Black patients were rarely included in clinical trials — until the COVID-19 vaccines. Will these changes stick?
June 30, 2022
From MarketWatch
From MarketWatch
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
May 27, 2022
From MarketWatch
From MarketWatch
From MarketWatch
This group of stocks is flagging a rebound, and that’s good news for the S&P 500, says technical analyst
March 22, 2022
From MarketWatch
From MarketWatch
‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data
February 07, 2022
From MarketWatch
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.